文献速递脊柱外科创伤骨科

万古霉素在后路脊柱融合术中减少手术部位感染的效果:STRIVE试验回顾性数据分析

Vancomycin Effectiveness in Reducing Surgical Site Infection in Posterior Spinal Fusion Surgery: A Retrospective Data Analysis of the STRIVE Trial.
PubMed 文献 · Spine (Phila Pa 1976) · 2026-02-27

本研究基于STRIVE试验中3311例后路脊柱融合手术患者的前瞻性数据,回顾性分析术中局部使用万古霉素与手术部位感染(SSI)的关系。结果显示,局部万古霉素使用与SSI发生率降低无关(OR 0.77,95%CI 0.42-1.42),但与再入院(OR 1.82)和再手术(OR 1.75)风险增加相关。

要点

  • 局部万古霉素未显著降低后路脊柱融合术后SSI发生率(OR 0.77,95%CI 0.42-1.42)。
  • 局部万古霉素与再入院(OR 1.82,P<0.001)和再手术(OR 1.75,P=0.005)风险增加相关。
  • 局部万古霉素使用与重症监护停留或脓毒症无显著关联。

核心结论

  • 与不使用局部抗生素相比,术中局部使用万古霉素与后路脊柱融合术后SSI发生率降低无关。

研究设计与样本

  • 对STRIVE试验中3595例患者的前瞻性数据进行回顾性分析,按局部抗生素使用分层,采用多因素logistic回归调整人口学和SSI相关危险因素。
  • 3311例手术患者中,847例(26%)仅接受局部万古霉素,1534例(46%)未接受局部抗生素。

主要发现

  • 局部万古霉素与SSI发生率无关(OR 0.77;95%CI 0.42-1.42),与重症监护停留(OR 0.94;95%CI 0.78-1.12)或脓毒症(OR 2.04;95%CI 0.62-6.73)也无关。
  • 局部万古霉素与再入院风险增加相关(OR 1.82;95%CI 1.28-2.6;P<0.001),与再手术风险增加相关(OR 1.75;95%CI 1.18-2.6;P=0.005)。
  • 与局部万古霉素使用相关的因素包括术中抗生素再次给药(OR 2.97;95%CI 1.36-6.5;P=0.006),以及医院位置:欧洲(OR 0.13;95%CI 0.06-0.29;P<0.001)和亚洲(OR 0.02;95%CI 0-0.08;P<0.001)低于北美。

临床怎么用

  • 在后路脊柱融合术中,不应仅以降低SSI为目的常规局部使用万古霉素,需权衡再入院和再手术风险。

局限性

  • 本研究为回顾性分析,尽管调整了混杂因素,仍可能存在未测量的混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective analysis of prospectively collected data. OBJECTIVE: To re-evaluate vancomycin as a preventive measure for surgical site infection (SSI). SUMMARY OF BACKGROUND DATA: Intrawound vancomycin powder is used to prevent SSIs in spinal surgery. Prior studies, often limited to single institutions or small samples, have shown mixed efficacy and potential increases in non- S. aureus and Gram-negative infections. We hypothesized that SSIs rates would be similar with and without intrawound vancomycin in posterior spinal fusion (PSF) surgery. METHODS: Prospectively collected data from the 3595 patients in the STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) trial were stratified by intrawound antibiotic usage. Multivariate logistic regression assessed the effect of vancomycin use on SSI, adjusting for patient demographics and SSI-associated risk factors. Secondary outcomes included critical care stay, reoperation, sepsis, and hospital readmission. RESULTS: Of 3311 patients who underwent surgery, 847 (26%) received only intrawound vancomycin and 1534 (46%) received no intrawound antibiotics. Sixty (8%) patients developed postoperative SSI, of whom 20 (33%) had received intrawound vancomycin. Receiving intrawound vancomycin was not associated with SSI incidence versus no intrawound antibiotics [odds ratio (OR): 0.77; 95% CI: 0.42-1.42], critical care stay (OR: 0.94; 95% CI: 0.78-1.12), or sepsis (OR: 2.04; 95% CI: 0.62-6.73). However, intrawound vancomycin was associated with increased odds of hospital readmission (OR: 1.82; 95% CI: 1.28-2.6; P < 0.001) and reoperation (OR: 1.75; 95% CI: 1.18-2.6; P = 0.005). Factors significantly associated with intrawound vancomycin use included intraoperative antibiotic readministration (OR: 2.97; 95% CI: 1.36-6.5; P =0.006) and hospital location, lower odds in Europe (OR: 0.13; 95% CI: 0.06-0.29; P < 0.001) or Asia (OR: 0.02; 95% CI: 0-0.08; P < 0.001) versus North America. CONCLUSIONS: Intraoperative vancomycin use was not associated with reduced SSI incidence compared with no intrawound antibiotics after PSF surgery. LEVEL OF EVIDENCE: Level II.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Joshi A, Schiedo RM, Bronheim RS, et al. Vancomycin Effectiveness in Reducing Surgical Site Infection in Posterior Spinal Fusion Surgery: A Retrospective Data Analysis of the STRIVE Trial. Spine (Phila Pa 1976). 2026. PMID: 41902726. doi:10.1097/BRS.0000000000005671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。